Myeloma Drug Therapy Has Improved Long-term Survival Rates
Adults with newly diagnosed multiple myeloma may see reduced disease progression with a daratumumab-based regimen.
Updated on Sept. 26, 2026 in Cancer
Live Poll
Do you trust that new medical research is significantly improving long-term cancer survival outcomes?
Results from the phase 3 PERSEUS trial demonstrate that adding subcutaneous daratumumab to standard treatment for newly diagnosed multiple myeloma significantly extends progression-free survival. This study offers new insights for transplant-eligible patients aged 18 to 70.
Why it matters
This regimen aims to improve outcomes across induction, consolidation, and maintenance phases of care. The findings represent a notable advancement in managing the disease and potentially delaying the need for subsequent treatments.
In the phase 3 PERSEUS trial, 81.1% of patients receiving daratumumab-based therapy remained progression-free at 72 months, compared to 56.1% in the control group. The study, which followed participants for a median of 81.3 months, also showed improved sustained minimal residual disease negativity.
The players
Erasmus MC Cancer Institute
The institution based in Rotterdam where lead study authors are affiliated for oncological research.
The details
Patients in the study received subcutaneous daratumumab co-formulated with recombinant human hyaluronidase PH20. This formulation allows for more efficient drug delivery into the body, which helps to target myeloma cells more effectively. The regimen is structured to support patients through induction, consolidation, and maintenance, with therapy discontinuation allowed for those who achieve sustained minimal residual disease negativity.
Timeline
• The clinical trial had a median follow-up duration of 81.3 months.
• Progression-free survival rates were measured at the 72-month mark.
Health Landscape
This development builds upon the ongoing research into daratumumab-based therapies for hematologic malignancies. It updates the long-term performance metrics established by the PERSEUS trial, furthering the evolution of induction and maintenance care for transplant-eligible patients.
If you or a loved one are navigating a new diagnosis of multiple myeloma, these results provide important information to discuss with your oncology team regarding potential treatment paths. Always consult your physician to understand how these findings apply to your specific health profile.
The takeaway
The addition of subcutaneous daratumumab to standard myeloma therapy has demonstrated a 65% reduction in the risk of disease progression or death. Patients should talk with their care team about whether such targeted therapies are appropriate for their specific diagnosis and treatment plan.
Further reading
For more context on current treatment strategies, visit the Cancer section.
More information
Review the full PERSEUS trial clinical registry page for further study details.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that new medical research is significantly improving long-term cancer survival outcomes?
